IP Library Granted Patent US 7,078,171
Granted Patent B2
US 7,078,171 · App. 10/258,930 · Granted Jul 18, 2006

Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,078,171
App. No.
10/258,930
Granted
Jul 18, 2006
Kind
B2
Abstract

Described herein are methods for identifying novel nucleic acid regulatory elements and compounds that modulate the regulation of such elements. Also described herein are nucleic acid sequence identified as novel nucleic acid regulatory elements and host cells containing such nucleic acid regulatory elements in a vector.

Claims (12)

1. A method of identifying one or more candidate compounds having an effect on expression of a gene of interest, said method comprising:

(a) identifying a 5′ or 3′ UTR sequence from a gene of interest;

(b) selecting host cells which express the gene that is endogenously associated with the UTR;

(c) stably transfecting one set of host cells with a test expression vector, said test vector comprising said 5′ or 3′ UTR sequence linked to, and positioned upstream or downstream, respectively, of a reporter gene construct (UTR/reporter), and stably transfecting another set of host cells with a control expression vector, said control vector comprising said reporter gene and lacking said UTR sequence (control/reporter);

(d) identifying whether said UTR sequence has a post-transcriptional regulatory function by assessing whether a first mRNA function of the UTR/reporter transcript is changed compared to the control/reporter transcript;

(e) determining whether the UTR regulatory function identified in step (d) is physiologically relevant by assessing whether said changed first mRNA function of the UTR/reporter transcript corresponds to the first mRNA function of the gene endogenously associated with the UTR;

(f) contacting said compound with an mRNA molecule comprising said UTR sequence; and

(g) measuring whether said compound alters a UTR-mediated effect.

2. The method of claim 1 , wherein said compound is contacted with a cell that expresses said mRNA molecule.

3. The method of claim 1 , wherein said UTR-mediated effect is a change in mRNA function.

4. The method of claim 1 , wherein said compound is contacted with said mRNA molecule in vitro, and further wherein said UTR-mediated effect is an interaction between an mRNA transcript comprising said UTR and an RNA binding protein.

5. The method of claim 2 , wherein the UTR-mediated effect is the expression of a gene linked to said UTR sequence.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Feb 27, 2006
From: S.R. ONE, LIMITED
To: MESSAGE PHARMACEUTICALS, INC.
Reel/Frame 017215/0571 →
CORRECTIVE RECORDATION FORM COVER SHEET FOR ASSIGNMENT REEL 014211 FRAME 0560 Recorded Feb 24, 2004
From: GIORDANO, ANTHONY; EDER, PAUL S.; MCGILL, DEBORAH BEACH; JOHANNES, GREGG
To: MESSAGE PHARMACEUTICALS, INC.
Reel/Frame 015030/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2003
From: GIORDANO, ANTHONY; EDER, PAUL S.; BEACH, DEBORAH; JOHANNES, GREG
To: MESSAGE PHARMACEUTICALS, INC.
Reel/Frame 014211/0560 →
CONVERTIBLE SECURED SUBORDINATED BRIDGE NOTE Recorded May 21, 2003
From: MESSAGE PHARMACEUTICALS, INC.
To: S.R. ONE, LIMITED
Reel/Frame 014103/0179 →